Increasing incidence and changing trends in etiology & survival rates in HCC in a European cohort
Koen C van Son, Kirsi MA van Eekhout, Judith de Vos-Geelen, Heinz-Josef Klümpen, Eric TTL Tjwa, Joep de Bruijne, Nadia Haj Mohammad, Dave Sprengers, Minneke J Coenraad, Frederike GI van Vilsteren, Otto M van Delden, Joost PH Drenth, Maarten E Tushuizen, Adriaan G Holleboom, Lydia G van der Geest, R Bart Takkenberg, for the Dutch Hepatocellular & Cholangio Carcinoma Group (DHCG) · 2026
Read Increasing incidence and changing trends in etiology & survival rates in HCC in a European cohort by Koen C van Son, Kirsi MA van Eekhout, Judith de Vos-Geelen, Heinz-Josef Klümpen, Eric TTL Tjwa, Joep de Bruijne, Nadia Haj Mohammad, Dave Sprengers, Minneke J Coenraad, Frederike GI van Vilsteren, Otto M van Delden, Joost PH Drenth, Maarten E Tushuizen, Adriaan G Holleboom, Lydia G van der Geest, R Bart Takkenberg, for the Dutch Hepatocellular & Cholangio Carcinoma Group (DHCG) (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13545717.txt.
Description
Koen C van Son and colleagues charted in 2026 how liver cancer is changing in the Netherlands, using the national cancer registry for every new case from 2014 through 2022. The cohort held 6,526 patients. Incidence, adjusted for age, climbed from 3.5 to 4.1 cases per 100,000 people over the period, even though rates fall in some other regions.
Alcohol-related liver disease remained the commonest cause, yet cases tied to fatty liver disease linked to metabolic problems grew fastest, at more than 8 percent a year. Survival stayed poor, with fewer than one in five patients alive at five years. Receiving treatment aimed at cure improved survival more than any other factor, which the authors say argues for better surveillance of at-risk patients.
Catalog record
| CREATOR | Koen C van Son, Kirsi MA van Eekhout, Judith de Vos-Geelen, Heinz-Josef Klümpen, Eric TTL Tjwa, Joep de Bruijne, Nadia Haj Mohammad, Dave Sprengers, Minneke J Coenraad, Frederike GI van Vilsteren, Otto M van Delden, Joost PH Drenth, Maarten E Tushuizen, Adriaan G Holleboom, Lydia G van der Geest, R Bart Takkenberg, for the Dutch Hepatocellular & Cholangio Carcinoma Group (DHCG) |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 30614 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |